規制動向
2026年9月27日•1分で読めます
FDA Approves ANDA 076233 for Paclitaxel Injection (Hospira)
The FDA granted approval for ANDA 076233, a Paclitaxel injectable (6 mg/mL) submitted by Hospira. Original approval 2002, labeling supplement 2007.
規制動向
2026年9月19日•1分で読めます
FDA Approves Gemcitabine Injection (ANDA079183)
The FDA has approved the ANDA for gemcitabine injection (ANDA079183) from Hospira, Inc., with details on submission history and labeling updates.
規制動向
2026年9月17日•1分で読めます
FDA Approves ANDA063264 for Amikacin Sulfate Injection
The FDA approved ANDA063264 for Amikacin Sulfate injectable by Hospira. The product is listed as discontinued and includes multiple labeling and manufacturing supplemental submissions.
規制動向
2026年9月11日•1分で読めます
FDA Approves ANDA206517 for Aztreonam Injectable Products
FDA has approved Hospira's aztreonam injectable (1 g and 2 g vials) for intramuscular and intravenous use under ANDA206517.
規制動向
2026年9月10日•1分で読めます
FDA Grants Approval for Metoprolol Tartrate Injectable (ANDA078085) by Hospira
The FDA has approved Hospira’s Metoprolol Tartrate injectable (ANDA078085), an intravenous prescription drug with a 1 mg/mL strength.
規制動向
2026年8月24日•1分で読めます
FDA Approves Ondansetron Injectable (ANDA077473)
The FDA has approved ANDA077473 for ondansetron injectable, manufactured by Hospira, for intramuscular and intravenous use.